M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.78 EUR -1.02% Market Closed
Market Cap: 108.1m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Intrinsic Value

MAAT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MAAT stock under the Base Case scenario is 7.9 EUR. Compared to the current market price of 7.78 EUR, Maat Pharma SA is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MAAT Intrinsic Value
7.9 EUR
Undervaluation 1%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Maat Pharma SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MAAT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MAAT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Maat Pharma SA

Provide an overview of the primary business activities
of Maat Pharma SA.

What unique competitive advantages
does Maat Pharma SA hold over its rivals?

What risks and challenges
does Maat Pharma SA face in the near future?

Has there been any significant insider trading activity
in Maat Pharma SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Maat Pharma SA.

Provide P/S
for Maat Pharma SA.

Provide P/E
for Maat Pharma SA.

Provide P/OCF
for Maat Pharma SA.

Provide P/FCFE
for Maat Pharma SA.

Provide P/B
for Maat Pharma SA.

Provide EV/S
for Maat Pharma SA.

Provide EV/GP
for Maat Pharma SA.

Provide EV/EBITDA
for Maat Pharma SA.

Provide EV/EBIT
for Maat Pharma SA.

Provide EV/OCF
for Maat Pharma SA.

Provide EV/FCFF
for Maat Pharma SA.

Provide EV/IC
for Maat Pharma SA.

Show me price targets
for Maat Pharma SA made by professional analysts.

What are the Revenue projections
for Maat Pharma SA?

How accurate were the past Revenue estimates
for Maat Pharma SA?

What are the Net Income projections
for Maat Pharma SA?

How accurate were the past Net Income estimates
for Maat Pharma SA?

What are the EPS projections
for Maat Pharma SA?

How accurate were the past EPS estimates
for Maat Pharma SA?

What are the EBIT projections
for Maat Pharma SA?

How accurate were the past EBIT estimates
for Maat Pharma SA?

Compare the revenue forecasts
for Maat Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Maat Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Maat Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Maat Pharma SA compared to its peers.

Compare the P/E ratios
of Maat Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Maat Pharma SA with its peers.

Analyze the financial leverage
of Maat Pharma SA compared to its main competitors.

Show all profitability ratios
for Maat Pharma SA.

Provide ROE
for Maat Pharma SA.

Provide ROA
for Maat Pharma SA.

Provide ROIC
for Maat Pharma SA.

Provide ROCE
for Maat Pharma SA.

Provide Gross Margin
for Maat Pharma SA.

Provide Operating Margin
for Maat Pharma SA.

Provide Net Margin
for Maat Pharma SA.

Provide FCF Margin
for Maat Pharma SA.

Show all solvency ratios
for Maat Pharma SA.

Provide D/E Ratio
for Maat Pharma SA.

Provide D/A Ratio
for Maat Pharma SA.

Provide Interest Coverage Ratio
for Maat Pharma SA.

Provide Altman Z-Score Ratio
for Maat Pharma SA.

Provide Quick Ratio
for Maat Pharma SA.

Provide Current Ratio
for Maat Pharma SA.

Provide Cash Ratio
for Maat Pharma SA.

What is the historical Revenue growth
over the last 5 years for Maat Pharma SA?

What is the historical Net Income growth
over the last 5 years for Maat Pharma SA?

What is the current Free Cash Flow
of Maat Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Maat Pharma SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Maat Pharma SA

Balance Sheet Decomposition
Maat Pharma SA

Current Assets 40.6m
Cash & Short-Term Investments 32.1m
Receivables 7.1m
Other Current Assets 1.5m
Non-Current Assets 10.3m
Long-Term Investments 200k
PP&E 8.5m
Intangibles 1.3m
Other Non-Current Assets 238k
Current Liabilities 14.7m
Accounts Payable 5.7m
Accrued Liabilities 1.6m
Other Current Liabilities 7.4m
Non-Current Liabilities 10.6m
Long-Term Debt 10.1m
Other Non-Current Liabilities 527k
Efficiency

Earnings Waterfall
Maat Pharma SA

Revenue
2.6m EUR
Cost of Revenue
-826k EUR
Gross Profit
1.7m EUR
Operating Expenses
-25.9m EUR
Operating Income
-24.2m EUR
Other Expenses
27k EUR
Net Income
-24.1m EUR

Free Cash Flow Analysis
Maat Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MAAT Profitability Score
Profitability Due Diligence

Maat Pharma SA's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Negative Operating Income
28/100
Profitability
Score

Maat Pharma SA's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

MAAT Solvency Score
Solvency Due Diligence

Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
46/100
Solvency
Score

Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MAAT Price Targets Summary
Maat Pharma SA

Wall Street analysts forecast MAAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAAT is 15.3 EUR with a low forecast of 13.94 EUR and a high forecast of 16.8 EUR.

Lowest
Price Target
13.94 EUR
79% Upside
Average
Price Target
15.3 EUR
97% Upside
Highest
Price Target
16.8 EUR
116% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MAAT?

Click here to dive deeper.

Dividends

Maat Pharma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for MAAT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MAAT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Maat Pharma SA

Country

France

Industry

Biotechnology

Market Cap

108.3m EUR

Dividend Yield

0%

Description

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

Contact

AUVERGNE-RHONE-ALPES
Lyon
70 Avenue Tony Garnier
+33428291400
www.maatpharma.com

IPO

2021-11-08

Employees

43

Officers

CEO, Co-Founder & Director
Mr. Herve Affagard
Co-Founder & Member of Scientific Advisory Board
Dr. Joel Dore Ph.D.
Co-Founder
Mr. Pierre Rimbaud
CFO & Financial Director
Ms. Sian Crouzet
Technology Director & Chief Technology Officer
Ms. Carole Schwintner
Chief Scientific Officer
Dr. Nathalie Corvaia Ph.D.
Show More
Head of Investor Relations
Guilhaume Debroas Ph.D.
Head of Clinical Development
Dr. Emilie Plantamura
Chief Business Officer
Mr. Jonathan Chriqui Pharm.D.
Chief Medical Officer
Dr. Gianfranco Pittari M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MAAT stock?

The intrinsic value of one MAAT stock under the Base Case scenario is 7.9 EUR.

Is MAAT stock undervalued or overvalued?

Compared to the current market price of 7.78 EUR, Maat Pharma SA is Undervalued by 1%.

Back to Top